Opinion|Videos|December 11, 2023
Novel Investigational Approaches For the Treatment of Neovascular AMD
Dr Paul Hahn and Dr Michael Cohen explore upcoming treatments featuring innovative mechanisms of action and novel delivery systems for addressing neovascular AMD.
Advertisement
Episodes in this series
1:00 Retina specialists’ wish list for innovative therapies
6:40 Home OCT
8:43 Extending treatment intervals beyond four months
9:40 Therapies in the pipeline
15:00 Need for long-term retinal fluid suppression
16:00 Gene therapy
22:00 Helping patients facing end-stage vision loss
Advertisement
Related to this article
The plasmid DNA immunotherapy Voceryq gained FDA accelerated approval after 27% of RRP-001 patients needed no surgery for 12 months.
IgAN late-breakers led the meeting, alongside new data on aspirin, dialysis access, donor pregnancy, potassium, and depression.
Experts discuss remibrutinib, the first FDA-approved therapy for symptomatic dermographism: RemIND data, bleeding counseling, and where it fits in practice
Five liver societies define ACLF as liver failure plus extrahepatic organ dysfunction or failure, with three grades and FDA-informed trial endpoints.
Five CHEST 2026 interviews cover nalbuphine ER for IPF cough, tozorakimab in COPD, depemokimab remission, AD109 in OSA, and robotic bronchoscopy.
Psoriasis advocates Nitika Chopra and Ayesha Patrick address common misconceptions, how patients can speak up, and simple tips for clinicians.
The FDA has pushed its decision on mitapivat for sickle cell disease to February 1, 2027, while it reviews updated safety data to decide whether a REMS is needed.
Lindsay Ackerman, MD, and Chris Bunick, MD, PhD, examine how ORAL Surveillance shaped JAK warnings and what long-term atopic dermatitis data show.
Advertisement
Advertisement
Trending on HCPLive
1
Experts Discuss PAH Treatment Selection and Access
2
Nalbuphine ER Rapidly Eases IPF Cough Burden, With Phil Molyneaux, MD, PhD
3
Imlifidase Opens a Transplant Window, With Oriol Bestard, MD, PhD
4
Mitapivat PDUFA Date for Sickle Cell Disease Extended to February 2027
5